Next earnings date: 6 Aug 2025

Inotiv, Inc. – NASDAQ:NOTV
Inotiv stock price today
Inotiv stock price monthly change
Inotiv stock price quarterly change
Inotiv stock price yearly change
Inotiv key metrics
Market Cap | 126.45M |
Enterprise value | 466.30M |
P/E | -0.33 |
EV/Sales | 0.79 |
EV/EBITDA | -2.15 |
Price/Sales | 0.19 |
Price/Book | 0.40 |
PEG ratio | N/A |
EPS | -2.53 |
Revenue | 568.70M |
EBITDA | 28.63M |
Income | -65.53M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | -58.22% |
Oper. margin | -31.52% |
Gross margin | 46.7% |
EBIT margin | -31.52% |
EBITDA margin | 5.04% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeInotiv stock price history
Inotiv stock forecast
Inotiv financial statements
$5
Potential upside: 194.11%
Analysts Price target
Financials & Ratios estimates
Mar 2023 | 151.46M | -9.62M | -6.36% |
---|---|---|---|
Jun 2023 | 157.46M | 1.84M | 1.17% |
Sep 2023 | 140.74M | -9.66M | -6.87% |
Mar 2024 | 119.03M | -48.07M | -40.39% |
2024-08-08 | -0.09 | -0.2 |
---|
Mar 2023 | 868666000 | 596.03M | 68.61% |
---|---|---|---|
Jun 2023 | 854834000 | 579.50M | 67.79% |
Sep 2023 | 856530000 | 588.04M | 68.65% |
Mar 2024 | 815378000 | 608.21M | 74.59% |
Mar 2023 | 12.83M | -8.40M | -1.16M |
---|---|---|---|
Jun 2023 | 3.69M | -4.49M | -1.04M |
Sep 2023 | 18.76M | -7.69M | -310K |
Mar 2024 | 16.91M | -4.58M | -1.17M |
Inotiv alternative data
Aug 2023 | 2,099 |
---|---|
Sep 2023 | 2,099 |
Oct 2023 | 2,099 |
Nov 2023 | 2,099 |
Dec 2023 | 2,099 |
Jan 2024 | 1,955 |
Feb 2024 | 1,955 |
Mar 2024 | 1,955 |
Apr 2024 | 1,955 |
May 2024 | 1,955 |
Jun 2024 | 1,955 |
Jul 2024 | 1,955 |
Inotiv other data
Period | Buy | Sel |
---|---|---|
Dec 2024 | 117500 | 0 |
Quarter | Transcript |
---|---|
Q2 2024 15 May 2024 | Q2 2024 Earnings Call Transcript |
Q1 2024 7 Feb 2024 | Q1 2024 Earnings Call Transcript |
Q4 2023 11 Dec 2023 | Q4 2023 Earnings Call Transcript |
Q3 2023 10 Aug 2023 | Q3 2023 Earnings Call Transcript |
Insider | Compensation |
---|---|
Mr. Robert W. Leasure Jr. (1960) Pres, Chief Executive Officer & Director | $797,400 |
Dr. John E. Sagartz D.V.M., DiplomateACVP, DVM, Ph.D. (1965) Chief Strategy Officer & Director | $386,900 |
Ms. Beth A. Taylor CPA (1965) Vice President of Fin. & Chief Financial Officer | $337,830 |
Inotiv: Turning Focus To Organic Growth
Inotiv: High Expenses Likely To Impair Long-Term Profitability
Inotiv (NOTV) Investor Presentation - Slideshow
Headwaters Capital - Inotiv: Transformation Into A Critical Full-Service Contract Research Organization
Inotiv: Leading Mid-Market CRO Ups Its Game
Avantor Stock: Growth At A Reasonable Price
-
What's the price of Inotiv stock today?
One share of Inotiv stock can currently be purchased for approximately $1.7.
-
When is Inotiv's next earnings date?
Inotiv, Inc. is estimated to report earnings on Wednesday, 6 Aug 2025.
-
Does Inotiv pay dividends?
No, Inotiv does not pay dividends.
-
How much money does Inotiv make?
Inotiv has a market capitalization of 126.45M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 14.27% to 490.74M US dollars. Inotiv made a loss 108.45M US dollars in net income (profit) last year or -$0.2 on an earnings per share basis.
-
What is Inotiv's stock symbol?
Inotiv, Inc. is traded on the NASDAQ under the ticker symbol "NOTV".
-
What is Inotiv's primary industry?
Company operates in the Healthcare sector and Medical - Diagnostics & Research industry.
-
How do i buy shares of Inotiv?
Shares of Inotiv can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Inotiv's key executives?
Inotiv's management team includes the following people:
- Mr. Robert W. Leasure Jr. Pres, Chief Executive Officer & Director(age: 65, pay: $797,400)
- Dr. John E. Sagartz D.V.M., DiplomateACVP, DVM, Ph.D. Chief Strategy Officer & Director(age: 60, pay: $386,900)
- Ms. Beth A. Taylor CPA Vice President of Fin. & Chief Financial Officer(age: 60, pay: $337,830)
-
How many employees does Inotiv have?
As Jul 2024, Inotiv employs 1,955 workers.
-
When Inotiv went public?
Inotiv, Inc. is publicly traded company for more then 27 years since IPO on 25 Nov 1997.
-
What is Inotiv's official website?
The official website for Inotiv is inotivco.com.
-
Where are Inotiv's headquarters?
Inotiv is headquartered at 2701 Kent Avenue, West Lafayette, IN.
-
How can i contact Inotiv?
Inotiv's mailing address is 2701 Kent Avenue, West Lafayette, IN and company can be reached via phone at +7 654634527.
-
What is Inotiv stock forecast & price target?
Based on 1 Wall Street analysts` predicted price targets for Inotiv in the last 12 months, the avarage price target is $5. The average price target represents a 194.11% change from the last price of $1.7.
Inotiv company profile:

Inotiv, Inc.
inotivco.comNASDAQ
1,955
Medical - Diagnostics & Research
Healthcare
Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It has an agreement with BioVaxys to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.
West Lafayette, IN 47906-1382
CIK: 0000720154
ISIN: US45783Q1004
CUSIP: 45783Q100